Clinical Trial Update: Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia [Phase 1]

View source ↗

Summary

This entry reports on a Phase 1 clinical trial evaluating the optimal dose of zanubrutinib for adults with immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 1 | Status: NOT_YET_RECRUITING